Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...